Ross Camidge, MD on Phase III ALTA-1L Trial Established ALUNBRIG as First-Line Treatment

Ross Camidge, MD on Phase III ALTA-1L Trial Established ALUNBRIG as First-Line Treatment

User Photo
Cancer-News

1 month
9 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Ross Camidge, MD, PhD on Takeda’s ALUNBRIG (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cancer.

Read here: https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

Up Next Autoplay
User Photo